These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 21501203)

  • 1. A review of tumour lysis syndrome with targeted therapies and the role of rasburicase.
    Bose P; Qubaiah O
    J Clin Pharm Ther; 2011 Jun; 36(3):299-326. PubMed ID: 21501203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis.
    Lopez-Olivo MA; Pratt G; Palla SL; Salahudeen A
    Am J Kidney Dis; 2013 Sep; 62(3):481-92. PubMed ID: 23684124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clarifying the role of rasburicase in tumor lysis syndrome.
    Sood AR; Burry LD; Cheng DK
    Pharmacotherapy; 2007 Jan; 27(1):111-21. PubMed ID: 17192165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome.
    Kennedy LD; Ajiboye VO
    J Oncol Pharm Pract; 2010 Sep; 16(3):205-13. PubMed ID: 19923162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies.
    Ribeiro RC; Pui CH
    Clin Lymphoma; 2003 Mar; 3(4):225-32. PubMed ID: 12672271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.
    Knoebel RW; Lo M; Crank CW
    J Oncol Pharm Pract; 2011 Sep; 17(3):147-54. PubMed ID: 20332174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of recombinant urate oxidase (rasburicase) for treatment and prophylaxis of hyperuricemia in children undergoing chemotherapy.
    Pession A; Barbieri E; Santoro N; Paolucci P; Porta F; Locatelli F
    Haematologica; 2005 Jan; 90(1):141-2. PubMed ID: 15642687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis.
    Feng X; Dong K; Pham D; Pence S; Inciardi J; Bhutada NS
    J Clin Pharm Ther; 2013 Aug; 38(4):301-8. PubMed ID: 23550846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
    Hummel M; Buchheidt D; Reiter S; Bergmann J; Adam K; Hehlmann R
    Eur J Haematol; 2005 Dec; 75(6):518-21. PubMed ID: 16313266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rasburicase: future directions in tumor lysis management.
    Hochberg J; Cairo MS
    Expert Opin Biol Ther; 2008 Oct; 8(10):1595-604. PubMed ID: 18774926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.
    Cheuk DK; Chiang AK; Chan GC; Ha SY
    Cochrane Database Syst Rev; 2014 Aug; (8):CD006945. PubMed ID: 25121561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rasburicase for the management of tumor lysis syndrome in neonates.
    McNutt DM; Holdsworth MT; Wong C; Hanrahan JD; Winter SS
    Ann Pharmacother; 2006; 40(7-8):1445-50. PubMed ID: 16868218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
    Hu S; Han Y; Zhang W; Zhang T; Yao X; Liu L
    J Med Econ; 2019 Aug; 22(8):742-750. PubMed ID: 30939962
    [No Abstract]   [Full Text] [Related]  

  • 14. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.
    Bosly A; Sonet A; Pinkerton CR; McCowage G; Bron D; Sanz MA; Van den Berg H
    Cancer; 2003 Sep; 98(5):1048-54. PubMed ID: 12942574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.
    Cheuk DK; Chiang AK; Chan GC; Ha SY
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD006945. PubMed ID: 28272834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-Dose Rasburicase Might Be Adequate To Overcome Tumor Lysis Syndrome In Hematological Malignancies.
    Yaman S; Başcı S; Turan G; Ulu BU; Yiğenoğlu TN; Dal MS; Kızıl Çakar M; Altuntaş F
    Clin Lymphoma Myeloma Leuk; 2022 Feb; 22(2):e71-e76. PubMed ID: 34565690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Single Low-Dose Rasburicase in Management of Tumor Lysis Syndrome in Leukemia and Lymphoma Patients.
    Gupta G; Seth T; Garg V; Juneja R; Mahapatra M; Datta SK; Upadhyay AD; Saxena R
    Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e99-e104. PubMed ID: 33039358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rasburicase: a new approach for preventing and/or treating tumor lysis syndrome.
    Bessmertny O; Robitaille LM; Cairo MS
    Curr Pharm Des; 2005; 11(32):4177-85. PubMed ID: 16375739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant urate oxidase (rasburicase) in the prophylaxis and treatment of tumor lysis syndrome.
    Jeha S; Pui CH
    Contrib Nephrol; 2005; 147():69-79. PubMed ID: 15604607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of tumor lysis syndrome in adults.
    Coiffier B; Riouffol C
    Expert Rev Anticancer Ther; 2007 Feb; 7(2):233-9. PubMed ID: 17288532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.